Thyroid cancers stand out among solid tumours because many of the tumour-initiating
genetic events have been identified. Mutations leading to constitutive activation of MAP …

Clinical staging predicts tumor behavior in many cases, but does not allow true
'personalization'of initial therapy or identify potential therapeutic targets for patients with …

Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There
are several histological variants such as papillary and follicular thyroid carcinoma. Many …

Its restricted occurrence makes BRAFV600E of clinical diagnostic utility (Xing, 2007; Zatelli
et al., 2009). Its carcinogenetic potential has been demonstrated in several different cell …

Differentiated thyroid cancers (DTCs) are primarily initiated by mutations that activate the
MAPK signaling cascade, typically at BRAF or RAS oncoproteins. DTCs can evolve to more …

Thyroid cancer constitutes a progressive continuum of disease ranging from indolent well-
differentiated carcinomas to aggressive poorly differentiated carcinomas and universally …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

Molecular biology in the last decades has given important contributions in the understanding
of the pathogenesis of thyroid cancer, and it is successfully used for the diagnosis of thyroid …

Thyroid carcinoma is the most common cancer in the endocrine system. Recent advances,
using next-generation sequencing, have shed light on the molecular pathogenesis of thyroid …

Thyroid cancer is the most common malignant tumor of the endocrine system and accounts
for approximately 1% of all newly diagnosed cancer cases. The most frequent type of thyroid …